| Literature DB >> 30951308 |
Sianne Schwikkard1,2, Hannah Whitmore2, Kamakshi Sishtla, Rania S Sulaiman3, Trupti Shetty, Halesha D Basavarajappa, Catherine Waller2, Alaa Alqahtani2, Lennart Frankemoelle1, Andy Chapman1, Neil Crouch4,5, Wolfgang Wetschnig6, Walter Knirsch6, Jacky Andriantiana7, Eduard Mas-Claret2, Moses K Langat2,5, Dulcie Mulholland2,5, Timothy W Corson.
Abstract
Excessive blood vessel formation in the eye is implicated in wet age-related macular degeneration, proliferative diabetic retinopathy, neovascular glaucoma, and retinopathy of prematurity, which are major causes of blindness. Small molecule antiangiogenic drugs are strongly needed to supplement existing biologics. Homoisoflavonoids have been previously shown to have potent antiproliferative activities in endothelial cells over other cell types. Moreover, they demonstrated a strong antiangiogenic potential in vitro and in vivo in animal models of ocular neovascularization. Here, we tested the antiangiogenic activity of a group of naturally occurring homoisoflavonoids isolated from the family Hyacinthaceae and related synthetic compounds, chosen for synthesis based on structure-activity relationship observations. Several compounds showed interesting antiproliferative and antiangiogenic activities in vitro on retinal microvascular endothelial cells, a disease-relevant cell type, with the synthetic chromane, 46, showing the best activity (GI50 of 2.3 × 10-4 μM).Entities:
Year: 2019 PMID: 30951308 PMCID: PMC6771261 DOI: 10.1021/acs.jnatprod.8b00989
Source DB: PubMed Journal: J Nat Prod ISSN: 0163-3864 Impact factor: 4.050